BRVE Braveheart Bio, Inc.
Fundamentals / CIK 0002131524 / USDBraveheart Bio, Inc. reported $514.5M in total assets through September 30, 2026 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open BRVE in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2026-- Sep 30, 2026
-
Operating Income FY 2026-- Operating profit
-
Net Income FY 2026-- GAAP bottom line
-
Diluted EPS FY 2026-- Split-adjusted
-
Free Cash Flow FY 2026-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$121.3M Total debt: $515K
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Research & Development | $17.54M | $11.12M | -- | $9.0K | $0 | -- |
| Total Operating Expenses | $30.15M | $15.88M | -- | $59.29M | $381K | -- |
| Operating Income | -$30.15M | -$15.88M | -- | -$59.29M | -$381K | -- |
| Interest Income | $3.71M | $889K | -- | $169K | $0 | -- |
| Net Income | -$26.50M | -$14.99M | -$14.28M | -$59.12M | -$381K | -$99K |
| Basic EPS | -$0.51 | -$10.99 | -- | -$10.05 | -$0.61 | -- |
| Diluted EPS | -$0.51 | -$10.99 | -- | -$10.05 | -$0.61 | -- |
| Basic Shares Outstanding | 52.1M | 1.7M | -- | 5.9M | 637.5K | -- |
| Diluted Shares Outstanding | 52.1M | 1.7M | -- | 5.9M | 637.5K | -- |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2025-12-31 |
|---|---|---|---|
| Cash & Cash Equivalents | $121.3M | $122.8M | $89.16M |
| Cash & Short-Term Investments | $503.5M | $122.8M | $89.16M |
| Total Current Assets | $359.6M | $123.4M | $89.28M |
| Property, Plant & Equipment, Net | $20K | $23K | $0 |
| Other Non-Current Assets | $98K | $70K | $70K |
| Total Non-Current Assets | $154.9M | $3.51M | $70K |
| Total Assets | $514.5M | $127.0M | $89.35M |
| Accounts Payable | $1.98M | $2.67M | $1.06M |
| Other Current Liabilities | $6.14M | -- | $0 |
| Total Current Liabilities | $16.67M | $9.06M | $5.24M |
| Other Non-Current Liabilities | $75K | $86K | $91K |
| Total Non-Current Liabilities | $175K | $284K | $91K |
| Total Liabilities | $16.85M | $9.34M | $5.33M |
| Total Debt (incl. Leases) | $515K | $575K | -- |
| Common Stock | $8.0K | $1.0K | $1.0K |
| Retained Earnings | -$122.4M | -$95.91M | -$66.05M |
| Accumulated Other Comp. Income | -$718K | -- | $0 |
| Total Stockholders' Equity | $497.6M | -$95.91M | -$65.87M |
| Total Equity | $497.6M | -$95.91M | -$65.87M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Net Income | -$26.50M | -$14.99M | -$14.28M | -$59.12M | -$381K | -$99K |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Current Ratio | 21.57x | 13.63x | -- | -- | -- | -- |
| Quick Ratio | 30.20x | 13.56x | -- | -- | -- | -- |
| Debt to Equity | 0.00x | -- | -- | -- | -- | -- |